The vertical reality
Most biotech companies start on QuickBooks or a similarly lightweight accounting platform, and for a small preclinical team burning a Seed or Series A round, that is usually the right call. The trouble starts when the company adds its first clinical trial, its first collaboration agreement, or its first subsidiary, and the finance team discovers that the system was never built to track project-level cost, multi-entity consolidation, or ASC 606/808 revenue recognition.
By the time this becomes obvious, the organization is usually managing 3 or 4 workarounds simultaneously: a spreadsheet for grant tracking, a separate tool for cap table and equity accounting, and a manual consolidation process for a newly formed subsidiary. Each workaround is manageable individually. Together, they add days to every close and create real audit risk heading into a Series C or an IPO readiness review.
How NetSuite helps
NetSuite gives a growing biotech a single system that can handle multi-entity consolidation, project and grant-level cost tracking, and configurable revenue recognition for the collaboration and license agreements that increasingly make up biotech revenue, without the company having to re-platform again at the next funding round.
The key is implementing it before the pain becomes acute. Organizations that wait until the audit findings pile up spend more on remediation than they would have spent on a proactive migration, and they do it under time pressure heading into a transaction.
Why Archer Insights
Archer Insights works exclusively with life sciences and healthcare organizations, which means the implementation is designed around biotech-specific requirements, ASC 808 collaboration accounting, grant compliance, and multi-entity structures for subsidiary formation, from day one, rather than retrofitted after a generalist partner delivers a standard financials-only build. For a biotech evaluating when to make this move, that specificity is the difference between an implementation that scales with the next 3 funding rounds and one that needs to be redone.